Umbilical cord-derived mesenchymal stem cells preconditioned with isorhamnetin: potential therapy for burn wounds

Figure 6 Gene expression analysis of burn wounds. Bar diagrams corresponding to gene expression analysis of interleukin (IL)-1β, IL-6, transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), Bcl-2 associated X (Bax), Bcl-2 and matrix metallopeptidase 9 (MMP-9) are shown in the burn wound control (at days 7 and 14) and experimental groups treated with normal untreated mesenchymal stem cells (MSCs) and preconditioned MSCs (IH + MSCs) at days 7 and 14 following 72 h of burn injury. The pattern of gene expression was time dependent; statistically significant downregulation of IL-1β (at day 14), IL-6 and Bax (days 7 and 14), and significant upregulation of TGF-β and MMP-9 (days 7 and 14), VEGF and Bcl-2 (day 7) in case of IH + MSCs as compared to burn control. Same pattern was observed in the case of normal MSCs for IL-1β, IL-6, Bax VEGF and Bcl-2 genes, while for TGF-β (day 14) and MMP-9 (day 7), the expression levels were non-significant. For statistical analysis, One way ANOVA was performed, followed by the Bonferroni post hoc test. Data are presented as the mean ± SE (n = 3). ^aP < 0.05, ^bP < 0.01 and ^cP < 0.001. IL: Interleukin; TGF-β: Transforming growth factor β; VEGF: Vascular endothelial growth factor; MMP-9: Matrix metalloproteinase-9.